🔗 Share this article

Given that the US continues making sweeping changes to its immunization recommendations, one figure appears in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on Covid shots throughout the pandemic and has focused upon possible deaths after Covid vaccination in her brief tenure at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Health officials were set to reveal major changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with much of the global community with insufficient data for public health gain. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Dr. Høeg is set to speak at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US so as to align more like the Danish model, a nation with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

Høeg has little discernible background in drug development, approval processes or leadership, which has been typical for previous directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a sizeable institution. She lacks background in industry regulation.”

Previous heads of CBER would “grasp legal statutes and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who led CBER have had.”

This division has an enormous portfolio at the FDA, she emphasized.

“Many people just focuses on the new drug program, but the generic program clears a multitude of generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and each of these must be managed,” she explained. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the job, which oversees over 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” Woodcock added.

Response and Contentious Programs

In response to concerns about Dr. Høeg's credentials and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “inquiries rely on inaccurate assumptions”.

“Her resume aligns with the duties of her position,” the official explained, citing the months Høeg spent guiding the agency head on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a controversial rapid therapy clearance system that reportedly troubled her former heads. “How are these medications being chosen for this fast-track system? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards laxer oversight of all drugs, except for immunizations.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if troubling, track record, Howard observe. She released a research paper using unconfirmed volunteer-provided data to assess the rate of myocarditis after COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the current administration included changing guidelines for novel immunizations and discontinuing “optional” vaccines, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed preventing young men from receiving Covid vaccines.

“She is an complete ideologue who starts off with her beliefs and reverse-engineers to accommodate the science in a very disingenuous, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|